Pipeline of ADHD Market (Attention Deficit Hyperactivity Disorder) Reviewed for H2 2015
PUNE, India, March 1, 2016 /PRNewswire/ --
New market research titled "ADHD (Attention Deficit Hyperactivity Disorder) - Pipeline Review, H2 2015" is a report that provides an overview of the ADHD's (Attention Deficit Hyperactivity Disorder) therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Company Profiles discussed in this report includes Alcobra Ltd, Amarantus Bioscience Holdings, Inc., APeT Holding BV, Arbor Pharmaceuticals, LLC., BCWorld Pharm Co. Ltd., Collegium Pharmaceutical, Inc., Curemark, LLC, Domain Therapeutics SA, DURECT Corporation, H. Lundbeck A/S, Heptares Therapeutics Limited, Highland Therapeutics, Inc., Hisamitsu Pharmaceutical Co., Inc., Integrative Research Laboratories Sweden AB, Intra-Cellular Therapies, Inc., KemPharm, Inc., Luc Therapeutics, Inc., Medgenics Inc., Merck & Co., Inc., Neos Therapeutics, Inc., NeuroDerm Ltd., Neurovance, Inc., P2D Bioscience, Polleo Pharma Limited, Reviva Pharmaceuticals Inc., Samyang Biopharmaceuticals Corporation, Shire Plc, Signature Therapeutics, Inc, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Inc., Taisho Pharmaceutical Holdings Co., Ltd., Tris Pharma, Inc. and Vernalis Plc.
Complete report on H2 2015 pipeline review of ADHD (Attention Deficit Hyperactivity Disorder) with 61 market data tables and 16 figures, spread across 188 pages is available at http://www.reportsnreports.com/reports/459922-attention-deficit-hyperactivity-disorder-adhd-pipeline-review-h2-2015.html
Drugs Profiles discussed in this report includes (nicotine + opipramol hydrochloride), amfetamine XR, AR-08, BCWPE-003, BLI-1008, BNC-375, CB-8411, centanafadine IR, centanafadine SR, CM-4612, CTX-1301, CTX-1302, dasotraline, dextroamphetamine, dextroamphetamine MR, eltoprazine, etiguanfacine guanfacine hydrochloride ER, histamine dihydrochloride, HTL-1071, IRL-752, ITI-214, KP-415 CR, lisdexamfetamine dimesylate, Metadoxine ER, methylphenidate hydrochloride, methylphenidate hydrochloride MR, methylphenidate hydrochloride SR, methylphenidate hydrochloride XR, MGS-0028, molindone hydrochloride ER, NFC-1, niacinamide CR, NT-0201, P-001, PBF-509, PD-2005, PD-2007, PFR-08001, PFR-8026, RP-5063, SHP-465, Small Molecules for Attention Deficit Hyperactivity Disorder, Small Molecules to Agonize GPR88 for Attention Deficit Hyperactivity Disorder and Schizophrenia, Small Molecules to Agonize NMDA2D for ADHD, Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders, Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD, Small Molecules to Modulate Choline Transporter for ADHD, TRI-102, V-81444, viloxazine hydrochloride, vortioxetine hydrobromide and VU-0238429.
Order a Purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=459922
This report provides comprehensive information on the therapeutic development for ADHD (Attention Deficit Hyperactivity Disorder), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for ADHD (Attention Deficit Hyperactivity Disorder) and special features on late-stage and discontinued projects.
Scope of this report: The report provides a snapshot of the global therapeutic landscape of ADHD (Attention Deficit Hyperactivity Disorder). The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities and also key players involved in the therapeutics development for ADHD (Attention Deficit Hyperactivity Disorder) and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects. A review of the ADHD (Attention Deficit Hyperactivity Disorder) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources, pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the ADHD (Attention Deficit Hyperactivity Disorder) pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.
Another newly published market research report titled on Addiction - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Addiction Pipeline market research report of 369 pages is available at http://www.reportsnreports.com/reports/468281-addiction-pipeline-review-h2-2015.html
About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
[email protected]
Connect With Us on:
Facebook: https://www.facebook.com/ReportsnReports/
LinkedIn: https://www.linkedin.com/company/reportsnreports
Twitter: https://twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml
Share this article